Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder

Phase 3

Completed

• Conditions: Panic Disorders

• Registration Number: NCT00195598
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine. An additional purpose of this pilot study is to obtain the tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-01
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-16
• Study First Posted: 2005-09-19
• Primary Completion: 2006-04
• Study Completion: 2006-04
• Status Verified: 2010-03
• Last Update Submitted: 2010-04-01
• Last Update Posted: 2010-04-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• Meet DSM IV criteria for Panic Disorder (with or without agoraphobia) for at least 3 months before study day 1.
• Have a minimum of 8 full-symptom panic attacks during the 4 weeks before the screening visit.
• Provide a written informed consent

Read More

Exclusion Criteria

• Treatment with Venlafaxine within 6 months of study day 1, as well Paroxetine
• Known hypersensitivity to Venlafaxine or related compounds as well to Paroxetine.
• Psychopharmacologic drugs within 14 days of study day 1

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
To evaluate the improvement of social function following therapy with Venlafaxine extended release (XR)in the Treatment of Panic Disorder in comparison to Paroxetine.

Secondary Outcome Measures

Name	Time	Method
Obtain the tolerability of using Venlafaxine extended release (XR) in the treatment of Panic Disorder in comparison to Paroxetine.